In the largest patent verdict in U.S. history, on June 29 a federal jury in Marshall, Texas, awarded a Johnson & Johnson subsidiary $1.67 billion in damages against J&J rival Abbott Laboratories. The award represents more than two-thirds of the $2.2 billion J&J sought.
Everything about the litigation was outsize. The two blockbuster arthritis drugs at the heart of the dispute, Abbott’s Humira and J&J’s Remicade, had nearly $10 billion in combined sales last year. J&J alleged in its complaint, filed in April 2007, that Abbott used patented antibodies in Humira that were developed by New York University and a J&J subsidiary, and licensed exclusively to J&J.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
